Clinical-stage Biotech Company Receives Positive Feedback For AI-based Cancer Vaccine

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has recently garnered positive feedback on its patent application for a novel AI-based method designed to identify cancer vaccine targets. This advancement represents a pivotal step in the development of personalized cancer treatments, offering the potential for more effective therapies uniquely tailored to individual patients' needs. $Evaxion Biotech (EVAX.US)$